CEO's Corner

  CEO's Corner   
 

When the late Dr. Paul I. Terasaki began his work in transplant medicine in 1950, the field was still in its early formation and efforts were being made to understand the challenges of ensuring successful organ and bone marrow transplants. His passion and focus was on improving patient health.

He determined that a major cause of chronic organ rejection was due to HLA antibodies and he pioneered a tissue typing test, which assessed the compatibility of organ donors and recipients. This test became the international standard for tissue typing and has been used for organ and bone marrow donors and recipients for over 50 years!

But Dr. Terasaki did not stop there; by finding a way to assess compatibility, he pursued the development and advancement of this technology and founded a company at the forefront of transplant diagnostics, One Lambda, in 1984. This company, built on the research conducted by Dr. Terasaki, aimed to improve patient outcomes by developing cutting-edge solutions and resources to laboratories and clinicians. His ability to translate his research from One Lambda to the health care industry allowed him to affect the lives of hundreds of thousands of transplant patients, and this impact is still felt today.

As researchers, it is in our nature to tackle challenges to improve the human condition. One of the ways we do this is by creating technology platforms that will serve to enhance the way we diagnose and treat patients. And like Dr. Terasaki, we aim to go further and prioritize ways we can translate our work to care for patients suffering from cancer, diabetes, cardiovascular diseases, chronic wounds, etc.

Translational work is important, now more than ever, and we are excited to welcome our new Chief Innovation Officer, Maurizio Vecchione, to lead our efforts. His passion for human health and expertise in translational science will support the research efforts of the Institute to rapidly bring our platforms to real-world applications.

Right now, the need and urgency to translate research rapidly is imperative not just to find a vaccine for COVID-19, but also to develop minimally-invasive technologies for testing and treatment and to create better materials for PPE to protect our frontline health care workers and patients. We are working to address these challenges and are inspired by Dr. Terasaki’s tireless dedication to research and his passion to advance technology to make an impact. As we envision a world where personalized medicine is available to all, we strive to translate our platforms quickly and responsibly to create positive change for patient care.

 
     

 

 

Our Locations

Follow Us